Attenuation of coxsackievirus B3 by VP2 mutation and its application as a vaccine against virus-induced myocarditis and pancreatitis

Jung Hyun Park, Dae Sun Kim, Young Joo Cho, Yeon Jung Kim, Soo Young Jeong, Seung Min Lee, Seong Joo Cho, Cheol-Won Yun, Inho Jo, Jae Hwan Nam

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Coxsackievirus B3 (CVB3) is a common agent of viral myocarditis, a major cause of sudden cardiac death, and ultimately dilated cardiomyopathy. However, there is no vaccine in clinical use. In this study, we identified the conserved amino acid sequences in the C-terminal region of the VP2 of the coxsackievirus B group and some echoviruses. The mutant virus, YYFF, with phenylalanines substituted for two tyrosines in these conserved sequences was highly attenuated in vivo and could induce a high neutralizing antibody titer and a cytotoxic T-lymphocyte response against CVB3. Thereby, mutant-virus-immunized mice showed a 100% survival rate and protection against inflammation of the heart and pancreas after lethal dose challenge. Thus, this mutant virus is a good candidate for an attenuated CVB3 vaccine.

Original languageEnglish
Pages (from-to)1974-1983
Number of pages10
JournalVaccine
Volume27
Issue number13
DOIs
Publication statusPublished - 2009 Mar 18

Fingerprint

myocarditis
Enterovirus
pancreatitis
Myocarditis
Pancreatitis
Human Enterovirus B
Vaccines
vaccines
Viruses
mutation
viruses
Mutation
mutants
Conserved Sequence
Sudden Cardiac Death
Dilated Cardiomyopathy
Cytotoxic T-Lymphocytes
Neutralizing Antibodies
Phenylalanine
cytotoxic T-lymphocytes

Keywords

  • Attenuated vaccine
  • Coxsackievirus
  • VP2

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Attenuation of coxsackievirus B3 by VP2 mutation and its application as a vaccine against virus-induced myocarditis and pancreatitis. / Park, Jung Hyun; Kim, Dae Sun; Cho, Young Joo; Kim, Yeon Jung; Jeong, Soo Young; Lee, Seung Min; Cho, Seong Joo; Yun, Cheol-Won; Jo, Inho; Nam, Jae Hwan.

In: Vaccine, Vol. 27, No. 13, 18.03.2009, p. 1974-1983.

Research output: Contribution to journalArticle

Park, Jung Hyun ; Kim, Dae Sun ; Cho, Young Joo ; Kim, Yeon Jung ; Jeong, Soo Young ; Lee, Seung Min ; Cho, Seong Joo ; Yun, Cheol-Won ; Jo, Inho ; Nam, Jae Hwan. / Attenuation of coxsackievirus B3 by VP2 mutation and its application as a vaccine against virus-induced myocarditis and pancreatitis. In: Vaccine. 2009 ; Vol. 27, No. 13. pp. 1974-1983.
@article{f97b62e739d946158c900e89dc5732d8,
title = "Attenuation of coxsackievirus B3 by VP2 mutation and its application as a vaccine against virus-induced myocarditis and pancreatitis",
abstract = "Coxsackievirus B3 (CVB3) is a common agent of viral myocarditis, a major cause of sudden cardiac death, and ultimately dilated cardiomyopathy. However, there is no vaccine in clinical use. In this study, we identified the conserved amino acid sequences in the C-terminal region of the VP2 of the coxsackievirus B group and some echoviruses. The mutant virus, YYFF, with phenylalanines substituted for two tyrosines in these conserved sequences was highly attenuated in vivo and could induce a high neutralizing antibody titer and a cytotoxic T-lymphocyte response against CVB3. Thereby, mutant-virus-immunized mice showed a 100{\%} survival rate and protection against inflammation of the heart and pancreas after lethal dose challenge. Thus, this mutant virus is a good candidate for an attenuated CVB3 vaccine.",
keywords = "Attenuated vaccine, Coxsackievirus, VP2",
author = "Park, {Jung Hyun} and Kim, {Dae Sun} and Cho, {Young Joo} and Kim, {Yeon Jung} and Jeong, {Soo Young} and Lee, {Seung Min} and Cho, {Seong Joo} and Cheol-Won Yun and Inho Jo and Nam, {Jae Hwan}",
year = "2009",
month = "3",
day = "18",
doi = "10.1016/j.vaccine.2009.01.008",
language = "English",
volume = "27",
pages = "1974--1983",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "13",

}

TY - JOUR

T1 - Attenuation of coxsackievirus B3 by VP2 mutation and its application as a vaccine against virus-induced myocarditis and pancreatitis

AU - Park, Jung Hyun

AU - Kim, Dae Sun

AU - Cho, Young Joo

AU - Kim, Yeon Jung

AU - Jeong, Soo Young

AU - Lee, Seung Min

AU - Cho, Seong Joo

AU - Yun, Cheol-Won

AU - Jo, Inho

AU - Nam, Jae Hwan

PY - 2009/3/18

Y1 - 2009/3/18

N2 - Coxsackievirus B3 (CVB3) is a common agent of viral myocarditis, a major cause of sudden cardiac death, and ultimately dilated cardiomyopathy. However, there is no vaccine in clinical use. In this study, we identified the conserved amino acid sequences in the C-terminal region of the VP2 of the coxsackievirus B group and some echoviruses. The mutant virus, YYFF, with phenylalanines substituted for two tyrosines in these conserved sequences was highly attenuated in vivo and could induce a high neutralizing antibody titer and a cytotoxic T-lymphocyte response against CVB3. Thereby, mutant-virus-immunized mice showed a 100% survival rate and protection against inflammation of the heart and pancreas after lethal dose challenge. Thus, this mutant virus is a good candidate for an attenuated CVB3 vaccine.

AB - Coxsackievirus B3 (CVB3) is a common agent of viral myocarditis, a major cause of sudden cardiac death, and ultimately dilated cardiomyopathy. However, there is no vaccine in clinical use. In this study, we identified the conserved amino acid sequences in the C-terminal region of the VP2 of the coxsackievirus B group and some echoviruses. The mutant virus, YYFF, with phenylalanines substituted for two tyrosines in these conserved sequences was highly attenuated in vivo and could induce a high neutralizing antibody titer and a cytotoxic T-lymphocyte response against CVB3. Thereby, mutant-virus-immunized mice showed a 100% survival rate and protection against inflammation of the heart and pancreas after lethal dose challenge. Thus, this mutant virus is a good candidate for an attenuated CVB3 vaccine.

KW - Attenuated vaccine

KW - Coxsackievirus

KW - VP2

UR - http://www.scopus.com/inward/record.url?scp=61349151123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61349151123&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2009.01.008

DO - 10.1016/j.vaccine.2009.01.008

M3 - Article

VL - 27

SP - 1974

EP - 1983

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 13

ER -